Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 17/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 16/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 16/20 | 0.64 |
| ▸ | LMNA | P02545 | 6/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.62 |
| ▸ | USP2 | O75604 | 14/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21977296 | 0.86 | CYP1A2 (0.65) | ADORA2AADORA1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL782939 | 0.84 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2C19LMNACYP3A4 | |
| SCHEMBL4341941 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1MAPK1HSD17B10TSHR | |
| SCHEMBL2981549 | 0.78 | ADORA2A (0.71) | ADORA2AADORA1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5128126 | 0.75 | ADORA2A (0.66) | ADORA2AADORA1MEN1KMT2A | |
| SCHEMBL5132410 | 0.73 | ADORA2A (0.67) | ADORA2AADORA1MEN1KMT2A | |
| SCHEMBL4358177 | 0.72 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19LMNACYP3A4 | |
| SCHEMBL4343779 | 0.72 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19LMNACYP3A4 | |
| SCHEMBL4358173 | 0.72 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19LMNACYP3A4 | |
| SCHEMBL8880387 | 0.71 | TNF (0.65) | CYP1A2CYP2C9CYP2C19LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569573-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569573-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569573-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| CN-101151254-A | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | UNIV GEORGIA (US) | 2008-03-26 | — | — | CN | disclosed |
| US-20070259823-A1 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259823-A1 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259823-A1 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1848697-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-7250421-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250421-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250421-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060223834-A1 | Diketo acids on nucleobase scaffolds as inhibitors of Flaviviridae | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2006083553-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060172973-A1 | Nucleobase substituted with a 2-hydroxy-4-oxobut-2-enoic acid or ester or a 1-hydroxy-3-oxopropenephosphonic acid or ester, e.g., Methyl 4-(1,3-dibenzyl-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)-2-hydroxy-4-oxobut-2-enoate | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223834-A1 | Diketo acids on nucleobase scaffolds as inhibitors of Flaviviridae | EIF2AK2, DCK, RNGTT | ADORA2A 1977/4885ADORA1 2769/4885CYP1A2 2697/4885 |
| US-20070259823-A1 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | DCK, DTYMK, DUT | ADORA2A 2671/4885ADORA1 2078/4885CYP1A2 4068/4885 |
| US-20060172973-A1 | Nucleobase substituted with a 2-hydroxy-4-oxobut-2-enoic acid or ester or a 1-hydroxy-3-oxopropenephosphonic acid or ester, e.g., Methyl 4-(1,3-dibenzyl-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)-2-hydroxy-4-oxobut-2-enoate | DUT, DERA, DCK | ADORA2A 1403/4885ADORA1 876/4885CYP1A2 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.